Physician profile
Bruce Altman
NPI 1336147784
$4,792.85
in general payments reported to CMS, 2019-2025
20 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $312 · 2021: $63.31 · 2022: $349 · 2023: $1,272 · 2024: $754 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,480.22 | 2022-2025 | Xen Glaucoma Treatment System, Lumigan, Alphagan P |
| Alcon Vision LLC | $762.25 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Allergan, INC. | $710.92 | 2019-2022 | |
| Glaukos Corporation | $491.29 | 2023-2025 | Radius Xr, Idose |
| Johnson & Johnson Surgical Vision, INC. | $308.51 | 2019-2024 | Tecnis Iol, Catalys System |
| Nova Eye, INC. | $273.12 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $268.02 | 2019 | |
| Carl Zeiss Meditec, INC. | $105.00 | 2019 | |
| Bausch & Lomb Americas INC. | $86.00 | 2023-2024 | Vyzulta, Miebo, Ic-8 Apthera Iol |
| Tarsus Pharmaceuticals, INC. | $58.26 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $40.46 | 2019-2020 | |
| New World Medical,INC. | $35.55 | 2019-2022 | |
| Eyepoint US, INC. | $31.06 | 2019 | |
| Lombart Brothers, INC. | $28.64 | 2021 | |
| Rayner Intraocular Lenses Limited | $28.43 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $23.11 | 2019 | |
| Oyster Point Pharma, INC. | $19.32 | 2025 | Ryzumvi, Tyrvaya |
| Harrow Eye, LLC | $18.70 | 2024 | |
| Horizon Therapeutics Plc | $12.84 | 2023 | Uplizna |
| Novartis Pharmaceuticals Corporation | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Altman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.